Alcon increases its acquisition offer for STAAR Surgical, emphasizing a final deal amid shareholder debates and delays in the ...

The team reviews acoltremon’s mechanism in promoting basal tear production and maintaining ocular surface health. The Viewpoints series “Reimagining Dry Eye Management: Targeting Tear Function for ...

They evaluate key efficacy data and patient outcomes from the COMET-2 and COMET-3 clinical trials. The Viewpoints series “Reimagining Dry Eye Management: Targeting Tear Function for Sustained Relief” ...

BCVA is inadequate for detecting visual disturbances in conditions like MacTel, which initially affect the parafoveal region. MacTel is often underdiagnosed due to its parafoveal pathology, which BCVA ...

Panelists discuss how faricimab’s dual VEGF-A and Ang-2 inhibition may offer vascular stability advantages over single-pathway blockade, despite ongoing questions about Ang-2’s independent therapeutic ...

Panelists discuss how aflibercept’s structural design and the higher molar dose of its 8-mg formulation enhance VEGF binding, treatment durability, and clinical predictability.

The study evaluated thermal dynamics associated with CW-TSCPC and TLT using MicroPulse technology, such as temperature peak, ...

Ocular Therapeutix announced it plans to accelerate its intended New Drug Application (NDA) for AXPAXLI (OTX-TKI) for the ...

The US Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval to EyeYon Medical for its US clinical study of EndoArt, which is currently designated by the FDA ...

Formosa and Rxilient have an exclusive licensing agreement for APP13007 commercialization, including regulatory and sales ...

ViaLase announced the first patient has been treated in its US-based Investigational Device Exemption (IDE) clinical trial ...

PainReform has released details on, and the commencement of, its development plan for OcuRing-K, including an upcoming phase 2 clinical trial. 1 ...